Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
O'Sullivan, B. P. & Freedman, S. D. Cystic fibrosis. Lancet 373, 1891–1904 (2009).
Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106, 18825–18830 (2009).
US Food and Drug Administration. FDA labeling information — Kalydeco. FDA website [online], (2012).
Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663–1672 (2011).
Sermet-Gaudelus, I. et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 182, 1262–1272 (2010).
Clancy, J. P. et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12–18 (2012).
Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 30 Jan 2012 (doi:10.1016/j.jcf.2011.12.005).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Pamela B. Davis has patents on gene therapy approaches to cystic fibrosis and other diseases that are currently licensed to Copernicus Therapeutics.
Rights and permissions
About this article
Cite this article
Davis, P., Yasothan, U. & Kirkpatrick, P. Ivacaftor. Nat Rev Drug Discov 11, 349–350 (2012). https://doi.org/10.1038/nrd3723
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3723
This article is cited by
-
Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis
Cell Biochemistry and Biophysics (2024)
-
Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis
Gene Therapy (2019)
-
High-throughput screen detects calcium signaling dysfunction in typical sporadic autism spectrum disorder
Scientific Reports (2017)
-
Pharmacogenomic information in drug labels: European Medicines Agency perspective
The Pharmacogenomics Journal (2015)
-
Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis
Molecular Therapy - Nucleic Acids (2013)
